Clinical Trials
Search Form
Disease Site | Trial Sort ascending | Trial Description | Trial Status | Lead Cooperative Group |
---|---|---|---|---|
Ovarian | ENGOT-OV24 / NSGO-AVANOVA2 |
Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. |
Completed | NSGO-CTU |
Ovarian | ENGOT-OV24 / NSGO-AVANOVA1 |
Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. |
Completed | NSGO-CTU |
Ovarian | CHRONO |
Retarded surgery following neoadjuvant chemotherapy in advanced ovarian cancer |
Recruiting | GINECO |
Ovarian | CHORUS |
A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma |
Completed | NCRI |
Ovarian | CCTG OV.25, STICS and STONES |
A randomized phase II double-blind placebo-controlled trial of Acetylsalicylic acid (ASA) in chemoprevention of ovarian cancer in women with BRCA1/2 mutations |
Closed to Recruitment | CCTG |
Ovarian | CCTG OV.21 |
A phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy |
Completed | CCTG |
Ovarian | AURELIA (GCIG/Roche) |
A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer |
Completed | GINECO |
Ovarian | ANITA/ ENGOT-Ov41/ GEICO 69-O |
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months |
Closed to Recruitment | GEICO |
Ovarian | AGO-OVAR23/DUO-O |
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib |
Follow Up | AGO |
Ovarian | AGO-OVAR17 |
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST) |
Completed | AGO |
Ovarian | AGO-OVAR16 (VEG110655) |
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy versus Placebo in Women who have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Completed | AGO |
Ovarian | AGO-OVAR12 (BI 1199.15) |
Multicenter, randomised, double-blind phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer |
Completed | AGO |
Ovarian | AGO-OVAR OP.7/TRUST |
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST) |
Follow Up | AGO |
Ovarian | AGO-OVAR 28 |
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane based Chemotherapy in Advanced Ovarian Cancer |
Recruiting | AGO |
Ovarian | AGO – OVAR OP.3 (LION) |
Lymphadenectomy In Ovarian Neoplasms |
Completed | AGO |
Ovarian & Endometrial Primary | LARA |
A Multicentre Phase II trial of Lenvatinib plus PembrolizumAb in Recurrent gynaecological clear cell Adenocarcinomas |
Recruiting | GCGS |
Ovarian Clear Cell | GCIG/JGOG3017 |
Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary |
Completed | JGOG |
Ovarian Newly Diagnosed | ENGOT-ov43/GOG-3036/MK-7339 |
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) |
Closed to Recruitment | BGOG |
Ovarian/Rare | ROCSAN |
A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy |
Recruiting | GINECO |
Ovarian/Rare | ALIENOR-GINECO-OV222 |
Efficacy and Safety of Bevacizumab (Avastin) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours |
Completed | GINECO |